Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Visit company website
5 years, 5 months ago
Ocugen, Inc is currently in a long term uptrend where the price is trading 42.1% above its 200 day moving average.
From a valuation standpoint, the stock is 1237.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 17564.7.
Ocugen, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 130.6% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 48.3% to $-5M since the same quarter in the previous year.
Based on the above factors, Ocugen, Inc gets an overall score of 2/5.